A single center randomized comparative study to know the effects of preoperative administration of atorvastatin on the plaque stability

A single center randomized comparative study to know the effects of preoperative administration of atorvastatin on the plaque stability - Atorvastatin Before Carotid Artery Revascularization Therapy (AB-CART)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005633

Enrollment

100

Registered

2011-06-01

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

carotid artery stenosis

Interventions

Atorvastatin 20mg/day for 4 weeks before revascularization Medical treatment without atorvastatin for 4 weeks before revascularization

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria 1) Patient whose age is between 20 and 80 years 2) LDL-cholesterol < 160mg/dL 3) 50% or more stenosis for the symptomatic patient or 80% or more stenosis for the asymptomatic patients who eligible for carotid revascularization 4) Patient who signed an informed consent form

Exclusion criteria

Exclusion criteria: Exclusion criteria 1) Patients who were administrated statins within a month 2) Patients who have liver dysfunction (ALT and/or AST > 100IU/L) 3) Patients who have kidney dysfunction (serum creatinine > 1.5 mg/dL) 4) Patients who have history of allergy to statins 5) Women who is wishing a baby, pregnant or nursing 6) Patients who are inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Volumetric changes of total plaque, lipid component, intraplaque hemorrhage on 3.0 Tesla MRI for the 4 weeks before revascularization	—

Secondary

Measure	Time frame
1) Change of max intima-media thickness(IMT) and peak systolic velocity(PSV) on carotid duplex scan for 4 weeks before revascularization 2) Number and volume of new high intensity spots on the DW-MRI within 3 days after revascularization 3) Serum lipid change (Total cholesterol, HDL-C, triglyceride and LDL-C) 4) Incidence of major cardiovascular events (non-fatal myocardial infarction, stroke, cardiovascular death and revascularization) for the 12 weeks after revascularization	—

Measure

Time frame

1) Change of max intima-media thickness(IMT) and peak systolic velocity(PSV) on carotid duplex scan for 4 weeks before revascularization 2) Number and volume of new high intensity spots on the DW-MRI within 3 days after revascularization 3) Serum lipid change (Total cholesterol, HDL-C, triglyceride and LDL-C) 4) Incidence of major cardiovascular events (non-fatal myocardial infarction, stroke, cardiovascular death and revascularization) for the 12 weeks after revascularization

—

Countries

Japan

Contacts

Public ContactShinichi Yoshimura

Graduate School of Medicine, Gifu University Department of Neurosurgery

s-yoshi@gifu-u.ac.jp+81-58-230-6271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026